Skip to main content
. 2022 Apr 16;107(7):e2680–e2689. doi: 10.1210/clinem/dgac217

Table 4.

Common adverse events in enliGHten trial

Preferred term Total, n (%)
(n = 298)
Any TEAE 195 (65.4)
 Upper respiratory infection 63 (21.1)
 Nasopharyngitis 33 (11.1)
 Cough 26 (8.7)
 Pyrexia 25 (8.4)
 Influenza 23 (7.7)
 Headache 21 (7.0)
 Viral upper respiratory tract infection 21 (7.0)
 Pharyngitis streptococcal 19 (6.4)
 Gastroenteritis 15 (5.0)

Proportions are based on subject-level counts.

Abbreviation: TEAE, treatment-emergent adverse event.